The Hague, Netherlands, 10th January 2022: Affidea, the largest European provider of diagnostic imaging, outpatient and cancer care services continues to invest in Italy and has today announced the 100% acquisition of Promea Center, a renowned outpatient provider in Piedmont region, Italy, specialized in outpatient services, day surgery and genetics.

This acquisition is the first in the 2022 announced by Affidea Group, following an impressive growth, with a total of 22 acquisitions made in the last two years, consolidating its leadership position across 15 countries and expanding now to 319 centers in Europe. Affidea has almost doubled its financial performance in the last 4 years.

Promea is a reputed outpatient medical center based in Turin, that has a Laboratory of Cytogenetics and Molecular Biology for the screening and diagnosis of genetic alterations, with specialization in Medically Assisted Procreation’s techniques. Promea also provides day surgery services (eye, vascular, aesthetic, etc.) and a wide range of specialist consultations (ophthalmology, orthopaedics, andrology, gynecology, etc.)

This investment strengthens Affidea’s presence in Italy, particulary in Piedmont, where Affidea has reached a leading position, growing now to 58 medical centers, serving more than 2.3 million patients per year with more than 2500 professionals. With this acquisition, Affidea diversifies and integrates its medical services in the region, stepping into day surgery, medically assisted procreation and genetics, successfully building a hub and spoke model which will offer patients a top-quality multi-service capacity, with full coverage of different diseases, from diagnosis to treatment and follow-up.

Promea also complements well Affidea’s IRMET center services with the genetic lab allowing Affidea to offer a 360° oncological diagnosis journey to its patients.

The deal was concluded as a result of a private negotiation where Affidea’s international reputation as a trusted business partner and high quality medical provider, was the key catalyst for securing the transaction.

Affidea continues to build scale in the existing geographies where Italy remains a key market, with the scope of creating synergies with its existing portfolio of services which will set Affidea as the preferred healthcare provider for individuals, corporations, private health insurers, and NHS.

Giuseppe Recchi, Affidea CEO, said on the Affidea’s latest investment in Italy: “2021 has been a growth record year for Affidea, in size and in revenues, almost doubling our financial performance versus the last 4 years. Only in 2021, we invested over EUR 270 million in M&A and greenfield centers, the most advanced digital infrastructure and state-of-the-art equipment. We completed 10 acquisitions, adding 47 new centers to our network and having now 50% of our total number of centers located across Western Europe. Thanks to our growth strategy, we transformed Affidea into the most advanced medical platform for high-quality integrated services, widely accessible to patients in need of diagnostic services, outpatient specialties and cancer care.

Business Affairs Homepage